Newsroom

Neuraxpharm launches its new name to support its strategic vision

NuPharm Group, a leading European specialty pharma company focussed on the treatment of central nervous system (CNS) disorders, has today announced that Dr. Jörg-Thomas Dierks has been appointed Chief Executive Officer (CEO) effective immediately. Jörg is replacing Stephan Walz, who has decided to step down in order to pursue other activities.

This strategic acquisition enables NuPharm to enter France and expand its European footprint

First acquisition made by Invent Farma / neuraxpharm following the creation of the Group by funds advised by Apax Partners in August 2016

Following to the acquisition of the operating subsidiaries of Invent Farma and neuraxpharm, the new group was created under the name NuPharm Group